Sepsis

16 trials 5 recruiting MedDRA PT
16 Registered trials
5 Recruiting
14 Unique sponsors
10 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 10
J Anti-infectives (ATC J) 4
P Parasitology (ATC P) 2
A Gastroenterology (ATC A) 1
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 8 substances
Azole antifungal 1 substance
Macrolide / aminoglycoside 1 substance
Phase III: 4 Phase II: 7 Phase III/IV: 1 Phase IV: 2 Phase I: 1 Phase I (Other): 1

Filter these 16 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 16 trials

Phase III

4 trials
  • Hellenic Institute For The Study Of Sepsis Academic
    IMP not specified
    2022-502962-26-00 1 country 2023 n=190
    Ended
  • Hellenic Institute For The Study Of Sepsis Academic
    CLARITHROMYCIN
    2023-507295-40-00 1 country 2024 n=330
    Recruiting
  • Hospices Civils De Lyon Academic
    DEXMEDETOMIDINE
    2025-524122-18-00 1 country n=360
    Pending
  • Oslo University Hospital HF Academic
    IMP not specified
    2024-520030-30-00 1 country 2025 n=50
    Recruiting

Phase II

7 trials
  • Novartis Pharma AG Commercial
    TIN816
    2023-505903-22-00 8 countries 2024 n=138
    Ended
  • Pfizer Inc. Commercial
    AVIBACTAM SODIUM; AZTREONAM; AZTREONAM, AVIBACTAM SODIUM; METRONIDAZOLE
    2022-501575-12-00 4 countries 2023 n=20
    Recruiting
  • Pfizer Inc. Commercial
    AZTREONAM, AVIBACTAM SODIUM; METRONIDAZOLE
    2023-507757-15-01 6 countries n=26
    Pending
  • Regeneron Pharmaceuticals Inc. Commercial
    REGN7544
    2024-514946-35-00 1 country 2025 n=31
    Ended
  • Centre Hospitalier Universitaire De Saint Etienne Academic
    IMP not specified
    2024-519783-41-00 1 country n=128
    Pending
  • Prinses Maxima Centrum voor Kinderoncologie B.V. Academic
    IMP not specified
    2025-524541-27-00 1 country n=76
    Pending
  • Universitaetsklinikum Aachen AöR Academic
    IMMUNOGLOBULIN A, IMMUNOGLOBULIN G, IMMUNOGLOBULIN M
    2024-513526-27-00 2 countries 2018 n=200
    Recruiting

Phase III/IV

1 trial
  • Azienda Ospedaliero-Universitaria Maggiore Della Carita Academic
    COLECALCIFEROL
    2024-515978-27-00 1 country n=552
    Pending

Phase IV

2 trials
  • Akershus University Hospital Academic
    IMP not specified
    2024-519797-39-00 1 country 2025 n=2,000
    Recruiting
  • Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela Academic
    IMP not specified
    2024-513890-30-00 1 country n=692
    Ended

Phase I

1 trial

Phase I (Other)

1 trial
  • Matisse Pharmaceuticals B.V. Commercial
    IMP not specified
    2024-512022-28-01 1 country 2025 n=15
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 2 Phase II 1
Hellenic Institute For The Study Of Sepsis Academic 2 Phase III 1
Bayer AG Commercial 1 Phase I 0
Matisse Pharmaceuticals B.V. Commercial 1 Phase I (Other) 0
Novartis Pharma AG Commercial 1 Phase II 0
Regeneron Pharmaceuticals Inc. Commercial 1 Phase II 0
Azienda Ospedaliero-Universitaria Maggiore Della Carita Academic 1 Phase III/IV 0
Centre Hospitalier Universitaire De Saint Etienne Academic 1 Phase II 0
Prinses Maxima Centrum voor Kinderoncologie B.V. Academic 1 Phase II 0
Universitaetsklinikum Aachen AöR Academic 1 Phase II 1
Hospices Civils De Lyon Academic 1 Phase III 0
Oslo University Hospital HF Academic 1 Phase III 1
Akershus University Hospital Academic 1 Phase IV 1
Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela Academic 1 Phase IV 0
New trials by year
2023
3
2024
2
2025
4
← All indication landscapes